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An epidemiological study in the Danish Greenland Inuit suggested a key role of fish oil (omega-3 fatty acids) in the prevention of atherosclerotic diseases^[@bib1])^. Following this landmark study, the health benefits of omega-3 fatty acids as part of a diet rich in fatty acids have been extensively researched, with large-scale epidemiological studies, clinical outcomes trials, and meta-analyses demonstrating statistically significant relative cardiovascular (CV) risk reductions with omega-3 fatty acids^[@bib2])^.

Hypertriglyceridemia is shown to be a major CV risk factor^[@bib3])^, and omega-3 fatty acids are reported to reduce serum triglyceride (TG) in patients with hypertriglyceridemia while at the same time increasing high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) levels, in addition to lowering small, dense LDL-C^[@bib2])^.

Although a highly purified eicosapentaenoic acid (EPA) preparation was developed and applied to humans in 1983 in Japan ahead of the rest of the world^[@bib4])^, omega-3 fatty acids have also been commercially available in many other parts of the world as Omacor/Lovaza (containing the same active ingredients as Lotriga^®^) (highly concentrated omega-3 fatty acid ethyl esters consisting of EPA ethyl ester (EPA-E) and docosahexaenoic acid ethyl ester (DHA-E) \[EPA-E/DHA-E\]). There were no direct comparisons between EPA-E alone versus EPA-E/DHA-E until a direct head-to-head comparison between EPA-E and EPA-E/DHA-E (Lotriga^®^) was made in a double blind (ORD) study of Japanese patients with hypertriglyceridemia for 12 weeks^[@bib5])^, in which the percent change in TG levels at the end of the study was −10.8 ± 22.6, −22.9 ± 23.1, and −11.2 ± 25.7 in the EPA-E/DHA-E 2 g/day, EPA-E/DHA-E 4 g/day, and EPA-E 1.8 g/day groups, respectively.

In this issue, Ta-Chen Su *et al.*, reported the efficacy and safety of Omacor^®^, a prescription ethyl-ester omega-3 fatty acid, in Taiwanese patients with hypertriglyceridemia for 8 weeks, in which the percent change in serum TG levels in both Omacor^®^ 4 g/day (−32.1%) and 2 g/day (−29.7%) groups was larger than that in the placebo group (−5.4%) (*p* \<0.001) without any drug-related serious adverse events^[@bib6])^. Interestingly, the reduction rates of serum TG levels in Taiwanese patients were larger than those in Japanese patients, and the two doses of 4 g/day and 2 g/day achieved a very similar percentage of TG reduction, although it is widely accepted that the effect of this drug is dose-dependent^[@bib7])^. The precise mechanism of these different results between the Japanese and Taiwanese patients is not known, but one possibility is the difference in lifestyle, especially food. Therefore, the clinical efficacy of omega-3 fatty acids might also be dependent on the life-style in each ethics, country, or area.

The effects of fish oil on CV diseases vary widely depending on the endpoints used and may be accounted for by the differences in the dosage of omega-3 fatty acids used, the duration of their use, and the patient background (particularly lifestyle, severity of disease, and use of concomitant medications) in the studies. Omacor^®^ has been used for 20 years in Western countries with several large-scale studies conducted in the meantime (**[Table 1](#T1){ref-type="table"}**), and it has been shown to be effective in secondary prevention of myocardial infarction^[@bib8])^, as well as in reducing all-cause mortality in patients with CHF^[@bib9])^. While Omacor^®^ has not been shown to be efficacious in all these studies^[@bib10],\ [@bib11])^, this may be due to the several major limitations, such as low dose of omega-3 fatty acids, insufficient statistical power, and patients populations whose baseline TG levels were normal or near normal^[@bib2])^.

###### Large-scale studies of Omacor^®^ (Lotriga^®^) conducted to date

  ----------------------------------------------------------------------------------------------------------
  Study                  GISSI-P^[@bib8])^   GISSI-HF^[@bib9])^   ORIGIN^[@bib11])^   GISSI-R&P^[@bib10])^
  ---------------------- ------------------- -------------------- ------------------- ----------------------
  Subject background     Prior MI\           CHF                  IGT/IFG/DM          Multiple CV risks
                         (within 3 mos)                                               

  Baseline TG (mg/dL)    162.1               NA                   *ω*-3 group: 142\   *ω*-3 group: 150\
                                                                  Control: 140        Control: 150

  Dose (g/day)           1                   1                    1                   1

  No. of subjects        11,324              7,046                12,612              12,513

  Follow-up (mos)        42                  47                   74.4                60

  CV event reduction     Yes                 Yes                  No                  No

  Statin use             29%                 23%                  54%                 62%

  Use of ACE-I/ARB       41%                 94%                  71%                 75%

  Use of antiplatelets   88%                 87%                  79%                 60%

  Study period           1993--1995          2002--2005           2003--2005          2004--2007
  ----------------------------------------------------------------------------------------------------------

From these viewpoints, two additional long-term CV interventional outcomes studies are ongoing using high-dose and prescription-strength omega-3 fatty acids. One is REDUCE-IT (NCT01492361) using Vascepa^®^ containing high-purity icosapent ethyl, the ethyl ester of EPA, and the other is STRENGTH (NCT02104817) using Epanova^®^, which contains omega-3 fatty carboxylic acids, to evaluate the reduction of CV events in patients at a high risk for CV events and with persistently high TG levels while on statin therapy. The results are highly anticipated to help clarify the potential role of omega-3 fatty acids in reducing CV risk.

Disclosures
===========

I Tatsuno received lecture fees from Takeda Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., AstraZeneca plc, and Mitsubishi Tanabe Co., Ltd.; received research grants from Takeda Pharmaceutical Co., Ltd., and Mochida Pharmaceutical Pharma Co., Ltd..; and was endowed a course at his affiliation by Fukuda Denshi Co., Ltd. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
